Blue Earth Therapeutics Advances with $76.5M Series A Financing for Next-Gen Radiohybrid RLTs

Funding:
Blue Earth Therapeutics has completed a $76.5M Series A financing round to accelerate the development of next-generation targeted radiohybrid RLTs.

Phase II Studies:
The company plans to initiate Phase II studies for these radiohybrid RLTs, focusing on improving their therapeutic efficacy.

Technological Advancements:
Blue Earth's modified linkers include a carboxylic acid side chain and a SiFa group to enhance albumin binding, overall charge, and internalization.

Differentiation Strategy:
The company aims to differentiate its beta emitter lutetium and alpha emitter technologies to offer more effective targeted therapies.